Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,580,091
  • Shares Outstanding, K 67,836
  • Annual Sales, $ 271,030 K
  • Annual Income, $ -186,570 K
  • 60-Month Beta 1.83
  • Price/Sales 23.82
  • Price/Cash Flow N/A
  • Price/Book 7.15
Trade RARE with:

Options Overview

Details
  • Implied Volatility 62.74%
  • Historical Volatility 42.64%
  • IV Percentile 44%
  • IV Rank 47.72%
  • IV High 80.84% on 11/02/20
  • IV Low 46.21% on 06/25/21
  • Put/Call Vol Ratio 0.31
  • Today's Volume 21
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 90
  • Open Int (30-Day) 560

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -1.40
  • Number of Estimates 10
  • High Estimate -1.12
  • Low Estimate -1.83
  • Prior Year -1.13
  • Growth Rate Est. (year over year) -23.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.36 +24.39%
on 08/20/21
104.38 -7.81%
on 09/07/21
+8.23 (+9.35%)
since 08/16/21
3-Month
76.78 +25.34%
on 08/03/21
104.38 -7.81%
on 09/07/21
-1.55 (-1.59%)
since 06/16/21
52-Week
76.78 +25.34%
on 08/03/21
179.65 -46.43%
on 12/24/20
+13.83 (+16.78%)
since 09/16/20

Most Recent Stories

More News
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029

Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users,...

RARE : 96.23 (-0.79%)
PTCT : 40.59 (+0.07%)
BMRN : 76.50 (-1.00%)
FIXX : 7.90 (unch)
RUBY : 20.30 (+1.50%)
SYBX : 3.19 (+0.63%)
Ultragenyx to Present at Morgan Stanley Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced...

RARE : 96.23 (-0.79%)
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita(TM) (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that Crysvita(TM) (Burosumab...

RARE : 96.23 (-0.79%)
Global Phenylketonuria Drugs Market- Analysis By Recent Trends, Development And Growth Forecast To 2027

Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users,...

RARE : 96.23 (-0.79%)
PTCT : 40.59 (+0.07%)
BMRN : 76.50 (-1.00%)
FIXX : 7.90 (unch)
RUBY : 20.30 (+1.50%)
SYBX : 3.19 (+0.63%)
Ultragenyx (RARE) Up 15% Since Last Earnings Report: Can It Continue?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RARE : 96.23 (-0.79%)
Ultragenyx Announces Approval of Dojolvi(R) (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Brazil's National...

RARE : 96.23 (-0.79%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant...

RARE : 96.23 (-0.79%)
Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate

The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.

PFE : 44.47 (-0.67%)
VRTX : 187.10 (-0.93%)
RARE : 96.23 (-0.79%)
CTLT : 138.17 (-0.07%)
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced...

RARE : 96.23 (-0.79%)
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.

VRTX : 187.10 (-0.93%)
RGEN : 299.88 (+1.17%)
VNDA : 16.25 (-0.55%)
RARE : 96.23 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

3rd Resistance Point 100.06
2nd Resistance Point 98.61
1st Resistance Point 97.42
Last Price 96.23
1st Support Level 94.78
2nd Support Level 93.33
3rd Support Level 92.14

See More

52-Week High 179.65
Fibonacci 61.8% 140.35
Fibonacci 50% 128.21
Fibonacci 38.2% 116.07
Last Price 96.23
52-Week Low 76.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar